The mitochondrial-targeted antioxidant MitoQ ameliorates metabolic syndrome features in obesogenic diet-fed rats better than Apocynin or Allopurinol
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
The prevalence of metabolic syndrome (MetS) components including obesity, dyslipidemia, insulin resistance (IR), and hepatic steatosis is rapidly increasing in wealthy societies. It is accepted that inflammation/oxidative stress are involved in the initiation/evolution of the MetS features. The present work was designed to evaluate the effects of three major cellular ROS production systems on obesity, glucose tolerance, and hepatic steatosis development and on oxidative stress onset. To do so, 40 young male Sprague-Dawley rats were divided into 5 groups: 1-control group, 2-high fat (HF) group (60% energy from fat), 3-HF+ MitoQ (mitochondrial ROS scavenger), 4-HF+ Apocynin (NADPH oxidase inhibitor), 5-HF+ Allopurinol (xanthine oxidase inhibitor). After 8 weeks of these treatments, surrogate MetS, mitochondrial function, and oxidative stress markers were measured in blood and liver. As expected, rats that were fed the HF diet exhibited increased body weight, glucose intolerance, overt hepatic steatosis, and increased hepatic oxidative stress. The impacts of the studied ROS inhibitors on these aspects of the MetS were markedly different. MitoQ showed the most clinically relevant effects, attenuating body weight gain and glucose intolerance provoked by the HF diet. Both Apocynin and Allopurinol showed limited effects suggesting secondary roles of xanthine oxidase (XO) or NADPH oxidase-dependent ROS production in the onset of oxidative stress-dependent obesity, glucose intolerance, and hepatic steatosis process. Thus, MitoQ revealed the central role of mitochondrial oxidative stress in the development of MetS and suggested that mitochondria-targeted antioxidants may be worth considering as potentially helpful therapies for MetS features.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Srere, P. A. (1969) · Methods in Enzymology · doi:10.1016/0076-6879(69)13005-0 · Cited by 2,005
Dandona, P., Aljada, A., Chaudhuri, A., Mohanty, P., & Garg, R. (2005) · Circulation · doi:10.1161/01.cir.0000158483.13093.9d · Cited by 1,263 · cited 1×
“Increased consumption of energy-dense foods containing high amounts of animal fats, saturated fatty acids, and fructose is thought to be the major contributor to the current epidemic of metabolic disorders [1,2].”
BackgroundAnderson, E. J., Lustig, M. E., Boyle, K. E., Woodlief, T. L., Kane, D. A., Lin, C.-T., Price, J. W., Kang, L., Rabinovitch, P. S., Szeto, H. H., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37048 · Cited by 1,253
Cross talk between mitochondria and NADPH oxidases
Dikalov, S. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.06.033 · Cited by 783
Apocynin Is Not an Inhibitor of Vascular NADPH Oxidases but an Antioxidant
Heumüller, S., Wind, S., Barbosa-Sicard, E., Schmidt, H. H. H. W., Busse, R., Schröder, K., & Brandes, R. P. (2008) · Hypertension · doi:10.1161/hypertensionaha.107.100214 · Cited by 735
Mitochondria-Targeted Small Molecule Therapeutics and Probes
Smith, R. A. J., Hartley, R. C., & Murphy, M. P. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.3969 · Cited by 399
Self-citationGane, E. J., Weilert, F., Orr, D. W., Keogh, G. F., Gibson, M., Lockhart, M. M., Frampton, C. M., Taylor, K. M., Smith, R. A. J., & Murphy, M. P. (2010) · Liver International · doi:10.1111/j.1478-3231.2010.02250.x · Cited by 379
Self-citationComparative pharmacology of chemically distinct nadph oxidase inhibitors
Wind, S., Beuerlein, K., Eucker, T., Müller, H., Scheurer, P., Armitage, M., Ho, H., Schmidt, H., & Wingler, K. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00920.x · Cited by 241 · cited 1×
“Many of the roles suggested for NOXs in various tissues and pathophysiological situations have been inferred from the in vitro and in vivo eff ects of several NOX inhibitors [18].”
BackgroundRodriguez-Cuenca, S., Cochemé, H. M., Logan, A., Abakumova, I., Prime, T. A., Rose, C., Vidal-Puig, A., Smith, A. C., Rubinsztein, D. C., Fearnley, I. M., et al. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.10.039 · Cited by 218
Self-citationMitochondria-targeted ubiquinone (MitoQ) decreases ethanol-dependent micro and macro hepatosteatosis
Chacko, B. K., Srivastava, A., Johnson, M. S., Benavides, G. A., Chang, M. J., Ye, Y., Jhala, N., Murphy, M. P., Kalyanaraman, B., & Darley-Usmar, V. M. (2011) · Hepatology · doi:10.1002/hep.24377 · Cited by 122 · cited 1×
“In an ATM / /ApoE / mice model, MitoQ decreased features of the MetS, including hepatic steatosis [27] whereas in alcoholic rats, MitoQ decreased ethanoldependent micro and macro hepatosteatosis [29].”
MethodSelf-citation
Cited by
Bhatti, J. S., Bhatti, G. K., & Reddy, P. H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.11.010 · Cited by 1,655
“Recent studies established the defensive action of MitoQ inmetabolic syndrome by affecting the redox signaling pathways [221,222].”
BackgroundLee, J. H., Park, A., Oh, K.-J., Lee, S. C., Kim, W. K., & Bae, K.-H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20194924 · Cited by 275
Linking mitochondrial dysfunction, metabolic syndrome and stress signaling in Neurodegeneration
Jha, S. K., Jha, N. K., Kumar, D., Ambasta, R. K., & Kumar, P. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.06.015 · Cited by 122
Crescenzo, R., Mazzoli, A., Di Luccia, B., Bianco, F., Cancelliere, R., Cigliano, L., Liverini, G., Baccigalupi, L., & Iossa, S. (2017) · Food & Nutrition Research · doi:10.1080/16546628.2017.1331657 · Cited by 63
“Accordingly, the flavonoid naringenin has been found to prevent oxidative stress and reduce insulin resistance in the liver of fructose-fed rats [44], and the mitochondria-targeted antioxidant mitoQ has been shown to ameliorate features of the metabolic syndrome in obesogenic diet-fed rats, thus revealing the central…”
BackgroundLi, G., Chan, Y., Sukjamnong, S., Anwer, A., Vindin, H., Padula, M., Zakarya, R., George, J., Oliver, B., Saad, S., et al. (2019) · Nutrients · doi:10.3390/nu11071669 · Cited by 40
Metadata
- Authors
- Feillet-Coudray, C., Fouret, G., Ebabe Elle, R., Rieusset, J., Bonafos, B., Chabi, B., Crouzier, D., Zarkovic, K., Zarkovic, N., Ramos, J., Badia, E., Murphy, M. P., Cristol, J. P., & Coudray, C.
- Venue
- Free Radical Research
- Publisher
- Informa UK Limited
- Published
- 2014-07-28
- Volume
- 48
- Issue
- 10
- Pages
- 1232-1246
- ISSN
- 1029-2470 (ISSN-L)
- 1071-5762
- OpenAlex
- W2100041443
- Cited by
- 76
- References
- 11
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The mitochondrial-targeted antioxidant MitoQ ameliorates metabolic syndrome features in obesogenic diet-fed rats better than Apocynin or Allopurinol. https://app.cochat.ai/papers/10.3109/10715762.2014.945079
- The paper
- Feillet-Coudray, C., Fouret, G., Ebabe Elle, R., Rieusset, J., Bonafos, B., Chabi, B., Crouzier, D., Zarkovic, K., Zarkovic, N., Ramos, J., Badia, E., Murphy, M. P., Cristol, J. P., & Coudray, C. (2014). The mitochondrial-targeted antioxidant MitoQ ameliorates metabolic syndrome features in obesogenic diet-fed rats better than Apocynin or Allopurinol. Free Radical Research. https://doi.org/10.3109/10715762.2014.945079
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.